Paper42467272
Bacteria mediated tumor therapy recent advances challenges and future perspectives.
Mao W and 1 other. Discov Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Bacteria mediated tumor therapy recent advances challenges and future perspectives. Papers, record 42467272. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42467272
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SYWD2024238 | Medical Innovation Application Research of Suzhou Science and Technology Bureau | PubMed | ||
| QNXM2024091 | Scientific research project of Suzhou Municipal Health Commissio | PubMed |
Source PubMed
References86
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34575965 | Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34575965 | PubMed |
| 2 | 35403784 | Decorating Bacteria with Triple Immune Nanoactivators Generates Tumor-Resident Living Immunotherapeutics. | Angew Chem Int Ed Engl | 2022 | https://conductscience.org/library/papers/35403784 | PubMed |
| 3 | 41083007 | Transdermal hydrogen therapy for psoriasis using cavity-embedded double-conical microneedles. | J Control Release | 2025 | https://conductscience.org/library/papers/41083007 | PubMed |
| 4 | 39089313 | Radiotherapy, immunity, and immune checkpoint inhibitors. | Lancet Oncol | 2024 | https://conductscience.org/library/papers/39089313 | PubMed |
| 5 | 37129253 | Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine. | ACS Nano | 2023 | https://conductscience.org/library/papers/37129253 | PubMed |
| 6 | 34534860 | Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery. | Biomaterials | 2021 | https://conductscience.org/library/papers/34534860 | PubMed |
| 7 | 41155984 | Engineered Bacteria-Nano Hybrid System: The Intelligent Drug Factory for Next-Generation Cancer Immunotherapy. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41155984 | PubMed |
| 8 | 38219524 | Engineering bacteria for cancer immunotherapy. | Curr Opin Biotechnol | 2024 | https://conductscience.org/library/papers/38219524 | PubMed |
| 9 | 35609407 | Dual drugs decorated bacteria irradiate deep hypoxic tumor and arouse strong immune responses. | Biomaterials | 2022 | https://conductscience.org/library/papers/35609407 | PubMed |
| 10 | 38909699 | Manganese-induced Photothermal-Ferroptosis for Synergistic Tumor Therapy. | J Control Release | 2024 | https://conductscience.org/library/papers/38909699 | PubMed |
| 11 | 39093127 | Early Detection of Malignant and Premalignant Peripheral Nerve Tumors Using Cell-Free DNA Fragmentomics. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/39093127 | PubMed |
| 12 | 39051784 | The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy. | Adv Healthc Mater | 2024 | https://conductscience.org/library/papers/39051784 | PubMed |
| 13 | 40953609 | Antisense oligonucleotide-loaded nanozyme reverses tumor immune suppression through sonogenetic metabolic therapy. | J Control Release | 2025 | https://conductscience.org/library/papers/40953609 | PubMed |
| 14 | 38987493 | Preparation of environmentally responsive PDA&DOX@LAC live drug carrier for synergistic tumor therapy. | Sci Rep | 2024 | https://conductscience.org/library/papers/38987493 | PubMed |
| 15 | 41128615 | Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives. | Protein Cell | 2026 | https://conductscience.org/library/papers/41128615 | PubMed |
| 16 | 40532565 | Nanozymes for regulation of reactive oxygen species in biomedical applications: Design, enzyme-like activity and therapeutic mechanisms. | Colloids Surf B Biointerfaces | 2025 | https://conductscience.org/library/papers/40532565 | PubMed |
| 17 | 39984501 | Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system. | Nat Commun | 2025 | https://conductscience.org/library/papers/39984501 | PubMed |
| 18 | 40480220 | Cellular mechanisms underlying beneficial versus detrimental effects of bacterial antitumor immunotherapy. | Immunity | 2025 | https://conductscience.org/library/papers/40480220 | PubMed |
| 19 | 32483165 | Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. | Nat Commun | 2020 | https://conductscience.org/library/papers/32483165 | PubMed |
| 20 | 40846311 | Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy. | Mol Pharm | 2025 | https://conductscience.org/library/papers/40846311 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42467272
GET https://conductscience.org/api/papers/v1/42467272/references?page=2